SVRN received a letter from Nasdaq stating that it no longer meets the terms necessary to be listed on the market. The stock slid 8% to $27.01 after the bell Friday.
Inovio Pharmaceuticals got accelerated approval from the Food and Drug Administration for its drug Voceryq. Shares nearly quadrupled to $2.21 in after-hours trading.
Intel shed another $1.5% to $64.77 after the bell, following a 29% drop in day trading, as investors were displeased with its latest earnings report.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments